Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pivotal, Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles

Trial Profile

A Pivotal, Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Drospirenone (Primary)
  • Indications Pregnancy
  • Focus Therapeutic Use
  • Sponsors Leon Farma

Most Recent Events

  • 11 Apr 2024 According to a ASKA Pharmaceutical media release, company will discuss the detailed results of the Trial in articles and at academic conferences.
  • 07 Jul 2020 Results published in the Exeltis USA Media Release.
  • 07 Jul 2020 According to a Exeltis USA media release, results from this study were published in Contraception.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top